Source comparison
What Does BPC-157 Actually Do — Research-Grade Peptide Comparison
BPC-157 VEGFR2 activation → angiogenesis and fibroblast migration Tendon repair acceleration (68% tensile strength at 14 days vs 41% control), gastric ulcer reduction (60–80% lesion area decrease), ligament healing with improved collagen alignment None. Zero c
This comparison does not assign a generated winner or score.
- BPC-157
- VEGFR2 activation → angiogenesis and fibroblast migration
- Tendon repair acceleration (68% tensile strength at 14 days vs 41% control), gastric ulcer reduction (60–80% lesion area decrease), ligament healing with improved collagen alignment
- None. Zero completed human trials as of 2026
- 10 mcg/kg to 10 mg/kg (rodent models, IP or subcutaneous)
- TB-500 (Thymosin Beta-4)
- Actin sequestration → cell migration and angiogenesis
- Wound closure acceleration, cardiac repair post-MI in mice, hair follicle stimulation
- Phase II trials for pressure ulcers showed modest improvement; no FDA approval
- 2–10 mg total dose (human extrapolation from veterinary use)
- GHK-Cu (Copper Peptide)
- Copper delivery to SOD enzymes → antioxidant and matrix remodeling
- Collagen synthesis stimulation, MMP modulation, wound contraction in dermal models
- Cosmetic trials show improved skin elasticity; no rigorous wound healing RCTs
- Topical 0.05–2% formulations; systemic dosing not established
- Assessment
- BPC-157 has the strongest preclinical evidence for structural tissue repair through direct growth factor receptor activation. But also the largest evidence gap due to complete absence of human trials
- TB-500 has limited human data suggesting safety but unclear efficacy; GHK-Cu is better studied topically than systemically
- For research applications requiring documented angiogenesis and collagen synthesis mechanisms, BPC-157 offers the clearest mechanistic pathway. With the caveat that all dosing is animal-derived
- Institutional review and animal protocol compliance required for any in vivo work